Annovis Bio Regains NYSE Compliance, Advances Neurodegeneration Drug

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company, has announced that it has regained compliance with New York Stock Exchange (NYSE) continued listing standards. The company, which is developing the drug candidate buntanetap for Alzheimer’s disease and Parkinson’s disease, implemented corrective measures to restore its market capitalization and stockholders’ equity above required thresholds. As a result, its common stock will continue trading on the NYSE under the ticker symbol ANVS. This development is crucial for the company as it seeks to advance its clinical programs and maintain investor confidence.

Annovis Bio is headquartered in Malvern, Pennsylvania, and its lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy designed to inhibit the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. The company’s focus on neurodegenerative diseases such as Alzheimer’s and Parkinson’s represents a significant area of unmet medical need, with millions of patients worldwide affected by these conditions.

The announcement was disseminated through MissionIR, a specialized communications platform that is part of the Dynamic Brand Portfolio @ IBN. MissionIR assists IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. The platform offers a range of services, including access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release distribution, social media distribution via IBN, and tailored corporate communications solutions. For more information about Annovis Bio, visit www.annovisbio.com and follow the company on LinkedIn, YouTube, and X.